10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23845888
DOI
10.1016/j.leukres.2013.06.019
PII: S0145-2126(13)00205-1
Knihovny.cz E-resources
- Keywords
- Adverse events, Combined regimens, Multiple myeloma, Prognostic factors, Response rate, Thalidomide,
- MeSH
- Bortezomib MeSH
- Time Factors MeSH
- Cyclophosphamide administration & dosage MeSH
- Dexamethasone administration & dosage MeSH
- Adult MeSH
- Remission Induction MeSH
- Boronic Acids administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Melphalan administration & dosage MeSH
- Survival Rate MeSH
- Young Adult MeSH
- Multiple Myeloma drug therapy mortality MeSH
- Follow-Up Studies MeSH
- Prednisone administration & dosage MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrazines administration & dosage MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Thalidomide administration & dosage MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Bortezomib MeSH
- Cyclophosphamide MeSH
- Dexamethasone MeSH
- Boronic Acids MeSH
- Melphalan MeSH
- Prednisone MeSH
- Pyrazines MeSH
- Thalidomide MeSH
We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.
References provided by Crossref.org
